Investigational Drug Information for Urapidil
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
What is the drug development status for Urapidil?
Urapidil is an investigational drug.
There have been 14 clinical trials for Urapidil.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 15th 2017.
The most common disease conditions in clinical trials are Hypertension, Stroke, and Hemorrhage. The leading clinical trial sponsors are National Health and Medical Research Council, Australia, The George Institute, and University Hospital, Strasbourg, France.
There are nine hundred and sixty-four US patents protecting this investigational drug and eight international patents.
Summary for Urapidil
| US Patents | 964 |
| International Patents | 8,629 |
| US Patent Applications | 3,489 |
| WIPO Patent Applications | 1,265 |
| Japanese Patent Applications | 1,039 |
| Clinical Trial Progress | Phase 3 (2017-06-15) |
| Vendors | 70 |
Recent Clinical Trials for Urapidil
| Title | Sponsor | Phase |
|---|---|---|
| Propofol EC50 for Inducing Loss of Consciousness in General Combined Epidural Anesthesia | wangjiangling | N/A |
| Efficacy and Safety Profile of Remimazolam-alfentanil Combination for ERCP Sedation | Tianjin Nankai Hospital | N/A |
| Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial | First Affiliated Hospital of Chengdu Medical College | Phase 3 |
Clinical Trial Summary for Urapidil
Top disease conditions for Urapidil
Top clinical trial sponsors for Urapidil
US Patents for Urapidil
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Urapidil | ⤷ Sign Up | Double-acylated GLP-1 derivatives | Novo Nordisk A/S (Bagsvaerd, DK) | ⤷ Sign Up |
| Urapidil | ⤷ Sign Up | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (Rochester, NY) UNIVERSITY OF KANSAS (Lawrence, KS) | ⤷ Sign Up |
| Urapidil | ⤷ Sign Up | Double-acylated GLP-1 derivatives | Novo Nordisk A/S (Bagsvaerd, DK) | ⤷ Sign Up |
| Urapidil | ⤷ Sign Up | Derivatives of GLP-1 like peptides, and uses thereof | Novo Nordisk A/S (Bagsvaerd, DK) | ⤷ Sign Up |
| Urapidil | ⤷ Sign Up | Ultra-pure agonists of guanylate cyclase C, method of making and using same | SYNERGY PHARMACEUTICALS, INC. (New York, NY) | ⤷ Sign Up |
| Urapidil | ⤷ Sign Up | Compositions containing polymeric, ionic compounds comprising imidazolium groups | BASF SE (Ludwigshafen, DE) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Urapidil
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Urapidil | China | CN104519902 | 2032-05-08 | ⤷ Sign Up |
| Urapidil | European Patent Office | EP2846823 | 2032-05-08 | ⤷ Sign Up |
| Urapidil | Spain | ES2770599 | 2032-05-08 | ⤷ Sign Up |
| Urapidil | Japan | JP2015517477 | 2032-05-08 | ⤷ Sign Up |
| Urapidil | Japan | JP6250034 | 2032-05-08 | ⤷ Sign Up |
| Urapidil | World Intellectual Property Organization (WIPO) | WO2013167454 | 2032-05-08 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
